Amarin Corporation Plc.

Amarin is committed to improving the lives of patients suffering from central nervous system and cardiovascular diseases. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs.

Amarin currently has a broad neuroscience development pipeline comprising four key clinical development programs plus several pre-clinical opportunities. Clinical programs include an oral formulation of apomorphine for treating advanced Parkinson's disease patients experiencing frequent “off” episodes; a treatment for memory and cognition; a nasal formulation of lorazepam for treating emergency epilepsy seizures in the out-patient setting; and brain targeted delivery of levodopa for Parkinson’s disease which utilizes Amarin’s targeted transport lipid technology.

Amarin has initiated a cardiovascular development program to capitalize on the known therapeutic benefits of unsaturated fatty acids in cardiovascular disease. Amarin plans to utilize its extensive know-how and experience in lipid science to develop a series of products targeting the vascular system, endothelial dysfunction and vascular re-modeling. Amarin intends to commence a series of clinical trials with AMR 101 (97% pure EPA) in dyslipidemia, the first of which will commence by the end of this year. In addition, Amarin intends to commence investigation of new compounds from its existing development portfolio for the treatment of metabolic syndrome and dyslipidemia.

Amarin also has a proprietary lipid-based technology platform for the targeted transport of molecules through the liver and/or to the brain that can be leveraged in a wide range of disease applications for its own product pipeline or with potential partners.